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Abstract
Vasoactive intestinal polypeptide (VIP) has been found in pancreatic nerves in several species. Studies were conducted to determine if
VIP could be a parasympathetic neurotransmitter in the canine endocrine pancreas. To verify that VIP is localized in pancreatic
parasympathetic nerves, sections of canine pancreas were immunostained for VIP. VIP staining was identified in the majority of neuronal
cell bodies in intrapancreatic parasympathetic ganglia. In addition, VIP was localized in nerve fibers innervating pancreatic islets in the
proximity of alpha cells. Next, to determine if VIP is released during electrical stimulation of parasympathetic nerves, pancreatic spillover
of VIP was measured during vagal nerve stimulation (VNS) in anesthetized dogs. VIP spillover increased from a baseline of 6306540
pg/min to 25806540 pg/min (D 5 1 19506490 pg/min, p , 0.01). Pancreatic VIP release during VNS was not affected by atropine,
whereas ganglionic blockade with hexamethonium nearly abolished the VIP response to VNS ( p , 0.005 vs control), suggesting that VIP
is a postganglionic neurotransmitter in the dog pancreas. To examine the effects of VIP on pancreatic hormone secretion, synthetic VIP
was infused locally into the pancreatic artery. VIP, at a low dose (5 pmol /min), increased glucagon secretion from 17506599 to
38006990 pg/min (D 5 1 20606870 pg/min, p , 0.05), but did not affect insulin secretion (D 5 2 10306760 mU/min, NS). Thus,
VIP is contained in and released from pancreatic parasympathetic nerves in proximity to islet alpha cells and exogenous VIP, at a dose
which approximates the increase of VIP spillover during VNS, preferentially stimulates glucagon vs insulin secretion. Therefore, VIP is
likely to function as a parasympathetic neurotransmitter in the endocrine pancreas in dogs. We hypothesize that VIP could mediate the
glucagon response to parasympathetic activation which has been shown to resistant to cholinergic blockade with atropine in several
species.  1997 Elsevier Science B.V.
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1. Introduction there is also evidence for peptidergic mediation of a
number of parasympathetic actions. For example, gastrin
Acetylcholine, via its action on muscarinic receptors, is release during vagal activation is not entirely blocked by
considered to be the primary post-ganglionic neurotrans- atropine, and a neuropeptide, gastrin releasing polypeptide,
mitter of the parasympathetic nervous system. However, contributes to vagally-induced gastrin release [1]. Similar-
ly, some of the pancreatic endocrine responses to vagal
* nerve stimulation are insensitive to muscarinic blockade byCorresponding author. Tel.: 1 1 916 7526553; fax: 1 1 916
7521297; e-mail: pjhavel@ucdavis.edu atropine. For example, we have found that atropine has no
0167-0115/97/$17.00  1997 Elsevier Science B.V. All rights reserved.
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effect on the glucagon response to vagal nerve stimulation, with a polyclonal antiserum to glucagon (dilution 1:1000),
but markedly reduces vagally-induced insulin secretion in followed by 1 h with fluorescein-labeled anti-rabbit IgG
dogs, whereas ganglionic blockade with hexamethonium (1:100; Jackson) [14,15]. The double-immunostained sec-
abolishes both responses [2]. Similar findings have been tions were viewed with a Zeiss Axioplan fluorescent
reported in other species [3,4]. These findings suggest that microscope equipped with a Hamamatsu C4880 fast-
one or more neuropeptides may be functioning as post- cooled integrating camera. Separate images were acquired
ganglionic parasympathetic neurotransmitters in the endo- using appropriate filters (rhodamine for VIP or fluorescein
crine pancreas [5,6]. for glucagon), then they were pseudo-colored (red for VIP
One such neuropeptide, vasoactive intestinal polypeptide and green for glucagon) and fused into a single image
(VIP) was among the first of a number of candidate using M2 software on the MCID image analysis system
neuropeptides found in pancreatic nerves [7]. VIP is (Imaging Research, Brock University, St. Catharines,
present in pancreatic nerves in several species [7–11] Ontario, Canada). Controls showed that no fluorescein
including humans [8,12,13] and results from one study fluorescence was visible when sections were viewed with
suggest that VIP is released from the pancreas and may rhodamine filters for Cy3, and Cy3 fluorescence was not
contribute to the vagal stimulation of pancreatic exocrine detected when sections were viewed with FITC filters.
secretion and blood flow in pigs [10].
In this study, we present evidence implicating VIP as a 2.2. Animals and surgical preparations
peptidergic neurotransmitter in the endocrine pancreas in
dogs. To that end, we first verified the localization of VIP Two types of experiments were performed. In one study,
in pancreatic parasympathetic ganglia by immunostaining. endogenous VIP release was measured before and during
We next examined pancreatic islets for the presence of VIP electrical vagal nerve stimulation. In the second study,
containing nerve fibers and the relationship of these nerves pancreatic hormones and VIP levels were measured before
with islet alpha-cells by dual immunostaining. We then and during infusion of exogenous VIP directly into the
quantified the amount of VIP released from the canine artery supplying the duodenal lobe of the pancreas. Mixed
pancreas during vagal nerve stimulation in anesthetized breed male dogs were fasted overnight prior to the
dogs and examined the effects of muscarinic blockade with procedures. Animals used in the experiments with exogen-
atropine or nicotinic, ganglionic blockade with hexameth- ous VIP infusion were anesthetized with intravenous
onium on vagally-induced pancreatic VIP release. Lastly, pentobarbital, sodium (30 mg/kg with a continuous infu-
21 1
we examined the effects of a local infusion of synthetic sion of 0.05 to 0.2 mg ? kg ? min ). Dogs were ventilated
VIP into the pancreatic artery on pancreatic hormone with room air (tidal volume 5 20 ml /kg) with a respirator.
secretion in anesthetized dogs. Animals used in the nerve stimulation experiments were
induced with intravenous injection of a short-acting barbi-
turate, thiamylal, sodium (20 mg/kg) and maintained on a
2. Materials and methods respirator connected to a vaporizer (Draeger, Germany)
supplying 0.8% halothane in oxygen. We have previously
2.1. Immunohistochemical studies demonstrated that this anesthetic regimen allows larger
pancreatic endocrine responses to electrical vagal nerve
Pancreas tissue was harvested at necropsy from purpose- stimulation than does pentobarbital which suppresses both
bred mongrel dogs of either sex. Small pieces of pancreas reflex vagal activation and nerve stimulation-induced
were fixed by overnight immersion in 4% paraformal- pancreatic polypeptide secretion [16].
dehyde in 0.1 M phosphate buffer at 48C, rinsed in 70% In both groups of dogs, a femoral artery (FA) was
ethanol, and embedded in paraffin. Immunohistochemistry catheterized for blood sampling and blood pressure mea-
was performed on 5 mm sections by indirect immuno- surement. A femoral vein was catheterized for infusion of
fluorescence. 0.9% saline and drugs. In all dogs, a midline laparotomy
For VIP immunostaining, a monoclonal antibody to VIP was performed and an extracorporeal shunt containing a
(kindly provided by Dr. Alison Buchan, University of sampling port, an electromagnetic flow probe (in Vivo
British Columbia, Vancouver, Canada) was used at a Metric Systems, Healdsburg, CA), and a heparin infusion
dilution of 1:20 000 (in 0.05 M PBS with 1% BSA) and line was placed between the superior pancreaticoduodenal
visualized using Cy3-labeled anti-mouse lgG at 1:100 vein (SPDV), the major vessel draining the right lobe of
(Jackson Immunoresearch Laboratories, West Grove, PA). the pancreas, and the portal vein. This preparation allows
Sections were mounted in glycerol and viewed with a the measurement of pancreatic hormone output [17] and
Nikon Microphot-FXA fluorescent microscope. For doub- neurotransmitter spillover [18,19] from the right lobe of
le-immunostaining of VIP and glucagon, sections were the pancreas. In dogs which received intrapancreatic
first incubated overnight with the VIP antibody followed infusions of VIP, the duodenum was surgically isolated
by 1 h incubation in the presence of Cy3-labeled anti- from the duodenal lobe of the pancreas as previously
mouse IgG. The sections were then incubated overnight described [18]. This procedure excludes the venous drain-
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age from the duodenum from reaching the SPDV and including humans, rats, pigs, and dogs. Paired blood
effectively converts this vessel into a superior pancreatic samples were drawn at 5, 10, 15, 20, and 30 min during,
vein (SPV). This procedure was not done in the vagal and at 5, 15, and 30 min after the VIP infusion was
nerve stimulation experiment since we have shown that discontinued. In all studies blood flow in the SPDV/SPV
duodenal exclusion abolishes pancreatic endocrine re- circuit was measured with an electromagnetic flowmeter,
sponses to vagal nerve stimulation [20], presumably be- (Model SV4F-4RD, Zepeda Instruments, Seattle, WA).
cause the vagal nerve fibers innervating the pancreas Hematocrit was determined at regular intervals throughout
traverse the duodenum. the experiments.
In order to assess pancreatic VIP release during vagal
nerve stimulation, the right and left branches of the 2.4. Assays
cervical vagal nerve trunks were isolated from the fascia
adjacent to the common carotid arteries [16]. The vagal Blood samples for glucose and insulin determination
trunks were cut between two ligatures and the distal were drawn and placed in tubes containing EDTA, for
segment of each was connected to a bipolar electrode glucagon determination in tubes containing heparin and
(Harvard Apparatus, South Natick, MA). The experimental benzamidine HCl, and for somatostatin and VIP determi-
protocols were conducted after a 1-h stabilization period. nation in tubes containing a solution of anticoagulants and
In dogs in which VIP was administered locally into the proteolytic enzyme inhibitors [22]. All samples were kept
arterial blood supplying the right lobe of the pancreas, a 22 on ice until centrifugation (20 min at 48C). The plasma
gauge Teflon catheter (Abbott, Inc., North Chicago, IL) was separated and frozen at 2 208C until assayed.
was inserted into the superior pancreatic artery [18]. Plasma glucose was assayed by the glucose oxidase
Adequate perfusion of the pancreas was verified at the method with a Technicon Autoanalyzer (Technicon Instru-
conclusion of each experiment by infusing a dye, sodium ments, San Francisco, CA). Plasma immunoreactive
indigotindisulfonate (Hynson, Wescott, and Dunning, glucagon (IRG) was measured by radioimmunoassay
Baltimore, MD), into the pancreatic arterial catheter. (RIA) in unextracted plasma with an antibody that has high
specificity for the C-terminal portion of the glucagon
2.3. Experimental protocols molecule [23]. Plasma immunoreactive insulin was mea-
sured by RIA with a modification of the double antibody
To assess pancreatic VIP release during electrical vagal technique of Morgan and Lazarow [24]. Plasma somato-
nerve stimulation, the vagal nerves were stimulated for 10 statin-like immunoreactivity was measured in unextracted
125
min with square-wave pulses of 5 ms duration and 13.5 plasma with an assay using [ I- Tyr11]somatostatin
mA current at a frequency of 10 Hz [15]. The stimulations tracer and an antibody (1:105 000 final dilution) which is
were performed with a Grass model S-44 stimulator with a directed against the central portion of the somatostatin-14
Grass PSIU6 constant current stimulus isolation unit molecule [25]. Plasma VIP was measured with a radioim-
125(Grass Instruments, Quincy, MA). Paired blood samples munoassay using an I-VIP tracer, a rabbit anti-VIP sera
were drawn from the FA and SPDV at 2 5 and 0 min (Calbiochem-Behring, La Jolla, CA,), and a sheep anti-
before, at 5 and 10 min during, and at 5 and 15 min after rabbit 2nd antibody [26].
the stimulation. Nerve stimulations were conducted under
control conditions during saline infusion, during mus- 2.5. Calculations and data analysis
carinic receptor blockade with atropine sulfate (Eli Lilly,
Indianapolis, IN) at a dose of 0.25 mg/mg 1 0.4 mg ? Pancreatic insulin, glucagon and somatostatin output
21 21kg ? min , or blockade of nicotinic ganglionic neuro- during VIP infusion was calculated as: [Hormone] 2SPV
transmission with hexamethonium bromide (Sigma Chemi- [Hormone] 3 Blood Flow [ the SPV 3 (1 2FA
cal, St Louis, MO) at a dose of 0.1 mg/kg 1 0.7 mg ? hematocrit). The changes of pancreatic hormone output
21 21kg ? min . The dose of atropine is sufficient to block were calculated by subtracting the mean of the 2 10 and 0
the cholinergically-mediated increase of pancreatic poly- minute baseline values from the mean of the 10, 15, 20,
peptide secretion during electrical vagal nerve stimulation and 30 minute values during the infusion of VIP. The
in dogs [21]. The dose of hexamethonium is sufficient to changes of VIP concentrations and pancreatic VIP output
eliminate all of the pancreatic endocrine response to vagal during vagal nerve stimulation were calculated by subtract-
nerve stimulation in dogs [2,21]. ing the mean of the 2 5 and 0 minute baseline values from
To examine the effects of exogenous VIP on pancreatic the mean of the 5- and 10-min values during nerve
hormone secretion, paired baseline blood samples were stimulation. Pancreatic VIP output during VIP infusion or
drawn from the FA and SPV at 2 10 and 0 min. Then neuronal VIP spillover during vagal nerve stimulation was
synthetic VIP (Peninsula Laboratories, Belmont, CA) dis- calculated as: [VIP] 2 [VIP] 3 SP(D)V BloodSP(D)V FA
solved in saline was infused into the pancreatic artery at a Flow 3 (1 2 hematocrit). This calculation slightly under-
dose of 5 pmol /min for 30 min at a rate of 0.1 ml /min. estimates pancreatic VIP release during vagal nerve stimu-
The sequence of VIP is identical in most mammals lation because the pancreas extracts approximately 50% of
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VIP arriving in the arterial blood (unpublished observation)
as it does the classical sympathetic neurotransmitter,
norepinephrine [27] and other neuropeptides such as
galanin [28].
The data are expressed as mean 6 SE. Statistical
comparisons of means within a group were made with a
paired t-test. For comparisons between groups, analysis of
variance was performed with a Dunnett’s post-test. P
values less than 0.05 were considered significant.
3. Results
3.1. VIP immunoreactive nerves in canine pancreas
To verify that canine pancreatic VIP-containing neurons
are parasympathetic, we immunostained sections of dog
pancreas for the presence of VIP immunoreactivity in
intrapancreatic ganglia, since these ganglia contain the
neuronal cell bodies which give rise to the post-ganglionic,
parasympathetic nerve fibers in the pancreas [29]. In every
intrapancreatic ganglion examined, VIP was observed in
the majority of neuronal cell bodies (Fig. 1 A and B and
Table 1). Small nerve trunks containing VIP-positive fibers
were sometimes observed emanating from intrapancreatic
ganglia (Fig. 1 B).
To determine whether these intrinsic VIP-containing Fig. 1. Presence of VIP immunoreactivity in neuronal cell bodies in dog
nerve fibers project to alpha cells in islets of the canine intrapancreatic ganglia. (A) Section of dog pancreas immunostained for
VIP, showing a large intrapancreatic ganglion with approximately 40 cellpancreas, we performed double-immunostaining of sec-
bodies. Approximately half of the neuronal cell bodies have VIPtions of dog pancreas for VIP and glucagon. The results
immunofluorescence, whereas in half of the cell bodies VIP immuno-
revealed numerous VIP-immunopositive nerve fibers inner- fluorescence appears either less intense or absent. (B) A separate section
vating pancreatic islets (Fig. 2A). Many of these fibers had of dog pancreas showing an intrapancreatic ganglion with 7–8 neuronal
a beaded appearance; these varicosities are presumably cell bodies, all with intense VIP immunofluorescence. Note nerve trunk
containing numerous fibers with VIP-immunoreactivity which appears tosites of ‘en passant’ release of VIP [30]. Such VIP-
exit ganglion. (in both figures, Bar 5 50 mm).containing varicosities were often found in close proximity
to glucagon-immunoreactive cells within islets (Fig. 2B).
Table 1
3.2. Effects of vagal nerve stimulation (VNS) on Proportion of neuronal cell bodies in large intrapancreatic ganglia
exhibiting VIP immunofluorescence in five sections of pancreas from fourpancreatic VIP release
dogs
Intensity of fluorescence 2 1 1 1 1 1 1 TotalElectrical stimulation of the cervical vagal trunks pro-
duced a small increase of arterial VIP, a quadrupling of No. of cell bodies 261 662 1062 962 2664
pancreatic venous VIP concentrations with little effect on % of cell bodies 764 2165 3566 37611 100
pancreatic vein blood flow. leading to a 3-fold increase of
pancreatic VIP spillover (Table 2).
Arterial VIP, pancreatic venous VIP, and VIP spillover
responses during atropine administration were similar to the pancreatic artery did not increase systemic (femoral)
those during the control saline infusions. The increase of arterial VIP levels (data not shown). However, pancreatic
pancreatic venous VIP concentrations during BCVNS was venous VIP levels increased significantly and pancreatic
markedly reduced by hexamethonium and the increment of vein blood flow increased by 81633% during VIP infu-
VIP spillover was inhibited by more than 90% (Fig. 3 sion, leading to a marked increase of pancreatic VIP output
Table 2). from 410680 to 52006840 pg/min (D 5 1 47806870
pg/min, p , 0.0025, Fig. 4A).
3.3. Effects of intra-pancreatic arterial (PA) infusion of Pancreatic arterial infusion of this dose of VIP more
exogenous VIP than doubled pancreatic glucagon output from 17506590
to 38006990 pg/min (D 5 1 20506870 pg/min; 1 2256
Infusion of a low dose of VIP (5 pmol /min) directly into 105%, p , 0.025, Fig. 4B). In contrast, VIP did not sig-
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Fig. 2. Innervation of dog pancreatic islets by VIP-containing nerve fibers. (A) Section of dog pancreas immunostained for VIP. Note beaded appearance of
VIP-immunopositive nerve fibers. (B) Section of dog pancreas was double-immunostained for the presence of VIP (red) and glucagon (green). The VIP and
glucagon immunostains were acquired separately using appropriate filters, pseudocolored red (VIP) or green (glucagon), and the two images fused to
produce the final figure as described in Section 2. Note presence of VIP-immunopositive nerve fibers in close proximity to glucagon-immunopositive cells.
(in both figures, Bar 5 25 mm).
Table 2
Plasma vasoactive intestinal polypeptide (VIP) concentrations and pancreatic VIP output (spillover from pancreatic parasympathetic nerves) before and
during vagal nerve stimulation (VNS).
Treatment VIP VIP BF VIP-outputFA SPDV SPDV
(pg/ml) (pg/ml) (ml /min) (pg/min)
BCVNS (control)
Baseline 3366 126653 9.161.0 6306290
During VNS 88630 505689 9.760.8 25806540
D 1 54628* 1 379668**** 1 0.760.8 19506490***
BCVNS (atropine)
Baseline 1746127 2516168 8.161.1 3806150
During VNS 2546173 5576256 9.261.3 19706440
D 1 80647 1 306693** 1 1.160.6 1 15906360***
BCVNS (hexamethonium)
Baseline 2665 43613 6.661.0 70640
During VNS 36615 93626 6.261.1 220680
D 1 1069 1 50619** 2 0.460.5 1 150670* ****
n 5 6 per treatment; values are means6SE.
FA 5 Femoral Artery; SPDV5 superior pancreaticoduodenal vein.
* 5 p , 0.05; ** 5 p , 0.025; *** 5 p , 0.01 vs baseline; **** 5 p , 0.005 vs control.
nificantly affect pancreatic insulin output which averaged 4. Discussion
546062540 mU/min before and 441061910 mU/min
during VIP infusion (D 5 10306760 mU/min; 2 2611%, In the present study, immunostaining of sections of dog
NS, Fig. 4C). Pancreatic somatostatin output increased pancreas revealed that the majority of cell bodies in
during VIP infusion from 11506210 to 15006210 fmol / intrapancreatic ganglia contain VIP. Since these ganglia are
min (D 5 1 3506170 fmol /min; 1 45621%, p , 0.05, the source of the parasympathetic, post-ganglionic nerves
data not shown). Plasma glucose was unchanged during which innervate the pancreas [29], our data suggest that the
VIP infusion averaging 11268 mg/dl prior to infusion and VIPergic nerves innervating the canine pancreatic islet are
11166 mg/dl during the infusion. intrinsic nerves of parasympathetic origin. This hypothesis
A ten-fold higher dose of VIP (50 pmol /min) infused is supported by other studies which demonstrated the
into the pancreatic artery produced a similar increase of presence of VIP immunoreactivity in neuronal cell bodies
glucagon output (D 5 1 173674%, p , 0.05), still no of intrapancreatic ganglia [7,11] and studies demonstrating
significant change of insulin output (D 5 1 26632%, NS), that extrinsic denervation of the canine pancreas did not
and larger increases of pancreatic somatostatin output (D 5 reduce the number of VIP containing nerves in the islet
1 119643%, p , 0.02) and pancreatic venous blood flow [9,11]. Further, we have observed that the majority of
(D 5 1 2956158%, p , 0.01) (data not shown). neuronal cell bodies in dog celiac ganglion, which supply
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Fig. 3. Pancreatic VIP output (spillover) before, during, and after vagal
nerve stimulation (VNS) in halothane-anesthetized dogs under control
(CONT) conditions, with administration of atropine (ATR), or with
administration of hexamethonium (HEX)(n 5 6 stimulations each).
the sympathetic post-ganglionic fibers that innervate the
islet [29], do not contain detectable VIP immunoreactivity
(unpublished observations), demonstrating that the VIP-
ergic nerve fibers innervating dog islets are not of sympa-
thetic origin.
The finding of VIP-containing neurons in the proximity
of pancreatic A-Cells provides morphologic support for
our hypothesis that VIP release from pancreatic nerves
regulates islet hormone secretion in the dog. These fibers
have the classical beaded appearance of peripheral au-
tonomic nerves (Fig. 3). The beads (or varicosities) have
been interpreted as multigranular release sites along the
length of these highly branched fibers [30]. Only rarely do
these beaded fibers appear to be in direct contact with
A-Cells, rather they appear to pass in close proximity to
A-cells (Fig. 3), presumably releasing VIP ‘en passant’.
This observation is consistent with that described for the
autonomic innervation of other tissues which also have few
direct synaptic contacts with autonomic nerves. Rather, the
target tissues appear to be exposed to neurotransmitters
that diffuse over a distances seven to one hundred times
greater than those of a true synaptic cleft [31,32].
VIPergic innervation of the pancreatic islet has also
been reported in other species, including humans [8,12,13],
rats [8], and pigs [10], although these studies did not
examine the specific innervation of A-cells. However, in
humans, VIP-positive nerve fibers were reported to form a
mesh around the islet periphery [8], where A-cells are most
abundant. These similarities in the relationship of VIPergic
nerves to A-cells in dogs and humans suggest that the dog
may be a good model for performing mechanistic studies
on the role of VIP in vagal regulation of the A-cell that
Fig. 4. (A) Pancreatic VIP output; (B) the change (A) of pancreatic
cannot be performed in humans. glucagon output, and; (C), insulin output before, during, and after the
We also report for the first time that VIP is released infusion of synthetic VIP (5 pmol /min) into the superior pancreatic artery
from the canine pancreas during vagal nerve stimulation. (PA) of seven halothane-anesthetized dogs.
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The magnitude of the pancreatic VIP spillover during vagal sible that VIP could help to mediate the increase of
nerve stimulation is similar to the VIP output measured glucagon secretion during insulin-induced hypoglycemia
during the low dose (5 pmol /min) intrapancreatic VIP since the pancreatic parasympathetic nerves are known to
infusion that stimulated glucagon secretion. Although the be activated during hypoglycemia [36,37]. Parasympathetic
neurally released VIP is not concentrated in a true synaptic activation, along with sympathoadrenal activation, is a
cleft (see above), the concentrations of VIP reaching the component of the redundant autonomic response which
A-cell are likely to be significantly higher during vagal contributes to increased glucagon secretion during hypo-
nerve stimulation than during intrapancreatic infusion of glycemia [38–42].
VIP.
Pretreatment with the muscarinic antagonist, atropine,
did not affect pancreatic VIP release during vagal nerve
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